Equities

Aprea Therapeutics Inc

APRE:NAQ

Aprea Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.01
  • Today's Change0.09 / 3.08%
  • Shares traded2.01k
  • 1 Year change-30.80%
  • Beta1.0535
Data delayed at least 15 minutes, as of Sep 20 2024 17:28 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy1
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for Aprea Therapeutics Inc have a median target of 16.00, with a high estimate of 20.00 and a low estimate of 11.00. The median estimate represents a 447.95% increase from the last price of 2.92.
High584.9%20.00
Med447.9%16.00
Low276.7%11.00

Earnings history & estimates in USD

On Aug 12, 2024, Aprea Therapeutics Inc reported 2nd quarter 2024 losses of -0.58 per share. This result exceeded the -0.64 consensus loss of the 2 analysts covering the company and exceeded last year's 2nd quarter results by 33.33%.
The next earnings announcement is expected on Nov 07, 2024.
Average growth rate+8.69%
Aprea Therapeutics Inc reported annual 2023 losses of -3.95 per share on Mar 26, 2024.
Average growth rate+18.97%
More ▼

Revenue history & estimates in USD

Aprea Therapeutics, Inc. had 2nd quarter 2024 revenues of 562.00k. This bettered the 50.00k consensus of the 2 analysts covering the company.
Average growth rate+650.23%
Aprea Therapeutics, Inc. had revenues for the full year 2023 of 583.00k.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.